RxDoctor Payments Data

Tessa Hancock, NP

Nurse Practitioner · Valdosta, GANPI 1346996048

Payments from drug & device makers

$803in general payments, 2019–2025

Across 52 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$310
  • Novo Nordisk$195
  • Astellas Pharma US Inc$95
  • Idorsia Pharmaceuticals US Inc$58
  • AstraZeneca$46
  • Pfizer$32
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$70888%
  • Education$9512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$803 in reported general payments places this provider in the 70th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$27,139
Medicare patients
161
Services billed
668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala30$122,746
MounjaroTirzepatide41$65,595
OzempicSemaglutide42$59,195
FarxigaDapagliflozin Propanediol24$21,745
EliquisApixaban22$19,731
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$17,658
LinzessLinaclotide13$13,633
JardianceEmpagliflozin13$12,588
MyrbetriqMirabegron13$8,876
Repatha SyringeEvolocumab15$6,867
Praluent PenAlirocumab11$6,433
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,651
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,118
Albuterol Sulfate HfaAlbuterol Sulfate81$1,884
Atorvastatin Calcium143$1,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$22$65,59541 claims
Novo NordiskOzempic$195$59,19542 claims
AstraZenecaFarxiga, Breztri Aerosphere$46$39,40346 claims
PfizerEliquis$32$19,73122 claims
AbbVieLinzess$15$13,63313 claims
Astellas Pharma US IncMyrbetriq$95$8,87613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →